Reports related to this article:
Project(s): View 2 related projects in PECWeb
Released February 27, 2018 | SUGAR LAND
en
Reported by Annette Kreuger, Industrial Info Resources (Sugar Land, Texas)--The European Pharmaceutical & Biotech Industry, better described as the Life Science Industry, includes the development and production of pharmaceuticals, biologicals, medical devices and cosmetics. Europe's volume of project activity continues to impress, all the more so, when the reported activity is expanded to include Russia and Turkey in Western Asia.
Click on the image at right for a graph detailing European Pharmaceutical-Biotech kickoffs planned for first -quarter 2018 by region.
With the $3.3 billion divided among 217 projects, the average total investment value (TIV) of each of the European projects is a healthy $15 million. All of this activity is not entirely unexpected. The very nature of the projects is a great representation of the industry's diverse and global pedigree.
Click on the image at right for a map of first-quarter Pharma-Biotech project starts in Europe.
From the well-established Western European market and a $184 million recombinant factor VIII plant expansion to produce hemophilia therapeutics in Germany, to a $406 million grassroot active pharmaceutical ingredient plant in Russia, the projects reflect the industry's global sprawl.
As far as project investment dollars, Western Europe is the first-quarter leader, with 65 projects expected to begin, representing a TIV of $1.2 billion. This is not surprising, as Western Europe is a mature industry market, long having established its place as major player.
Northern Europe, another industry stalwart, slid into second place, with $820 million being invested into 58 projects. Like Western Europe, the projects kicking off in the first quarter run the gamut from complex manufacturing plans to boosting the institutional research infrastructure.
Russia, underscoring the country's commitment in the form of its "Pharma Strategy 2020," a plan to boost domestic production of pharmaceutical and medical device products, managed to claim number three for the first quarter. A total of $659 million is planned for nine projects.
Click here for the 2018 North America Pharmaceutical & Biotech Industry Outlook.
With it being a bit more than midway in the first quarter, there remains a chance that a percentage of these projects will be delayed or put on hold. Nothing is ever definite until construction begins--and even then, changes happen. Each project will be tracked and updated. Some may be dropped altogether, while new ones are uncovered.
Industrial Info Resources (IIR), with global headquarters in Sugar Land, Texas, six offices in North America and 12 international offices, is the leading provider of global market intelligence specializing in the industrial process, heavy manufacturing and energy markets. Industrial Info's quality-assurance philosophy, the Living Forward Reporting Principle, provides up-to-the-minute intelligence on what's happening now, while constantly keeping track of future opportunities. Follow IIR on: Facebook - Twitter - LinkedIn. For more information on our coverage, send inquiries to info@industrialinfo.com or visit us online at http://www.industrialinfo.com.
Click on the image at right for a graph detailing European Pharmaceutical-Biotech kickoffs planned for first -quarter 2018 by region.
With the $3.3 billion divided among 217 projects, the average total investment value (TIV) of each of the European projects is a healthy $15 million. All of this activity is not entirely unexpected. The very nature of the projects is a great representation of the industry's diverse and global pedigree.
Click on the image at right for a map of first-quarter Pharma-Biotech project starts in Europe.From the well-established Western European market and a $184 million recombinant factor VIII plant expansion to produce hemophilia therapeutics in Germany, to a $406 million grassroot active pharmaceutical ingredient plant in Russia, the projects reflect the industry's global sprawl.
As far as project investment dollars, Western Europe is the first-quarter leader, with 65 projects expected to begin, representing a TIV of $1.2 billion. This is not surprising, as Western Europe is a mature industry market, long having established its place as major player.
Northern Europe, another industry stalwart, slid into second place, with $820 million being invested into 58 projects. Like Western Europe, the projects kicking off in the first quarter run the gamut from complex manufacturing plans to boosting the institutional research infrastructure.
Russia, underscoring the country's commitment in the form of its "Pharma Strategy 2020," a plan to boost domestic production of pharmaceutical and medical device products, managed to claim number three for the first quarter. A total of $659 million is planned for nine projects.
Click here for the 2018 North America Pharmaceutical & Biotech Industry Outlook.
With it being a bit more than midway in the first quarter, there remains a chance that a percentage of these projects will be delayed or put on hold. Nothing is ever definite until construction begins--and even then, changes happen. Each project will be tracked and updated. Some may be dropped altogether, while new ones are uncovered.
Industrial Info Resources (IIR), with global headquarters in Sugar Land, Texas, six offices in North America and 12 international offices, is the leading provider of global market intelligence specializing in the industrial process, heavy manufacturing and energy markets. Industrial Info's quality-assurance philosophy, the Living Forward Reporting Principle, provides up-to-the-minute intelligence on what's happening now, while constantly keeping track of future opportunities. Follow IIR on: Facebook - Twitter - LinkedIn. For more information on our coverage, send inquiries to info@industrialinfo.com or visit us online at http://www.industrialinfo.com.
